ClinicalTrials.Veeva

Menu

Far Infrared Irradiation for Control, Management and Treatment of Amyotrophic Lateral Sclerosis (ALS)

G

GAAD Medical Research Institute Inc.

Status and phase

Unknown
Phase 1

Conditions

Amyotrophic Lateral Sclerosis

Treatments

Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Radiation: Far infrared radiation

Study type

Interventional

Funder types

Other

Identifiers

NCT00673140
GAAD-ALS-CTP1

Details and patient eligibility

About

Amyotrophic Lateral Sclerosis (ALS, sometimes called Lou Gehrig's s Disease, or Maladie de Charcot) is a progressive, usually fatal, neurodegenerative disease caused by the degeneration of motor neurons, the nerve cells in the central nervous system that control voluntary muscle movement.

This study will investigate the use of far infrared radiation for the control, management and treatment of ALS.

Full description

As a motor neuron disease, ALS causes muscle weakness and atrophy throughout the body as both the upper and lower motor neurons degenerate, ceasing to send messages to muscles. Unable to function, the muscles gradually weaken, develop fasciculations (twitches) because of denervation, and eventually atrophy due to that denervation. The patient may ultimately lose the ability to initiate and control all voluntary movement except of the eyes.

Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells.

It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have ALS.

Enrollment

7 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with ALS

Exclusion criteria

  • None

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

7 participants in 1 patient group

1
Experimental group
Description:
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Treatment:
Radiation: Far infrared radiation
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems